**** Elite Pharmaceuticals Conference Call Questions ****
Those participating in ELTP’s Conference Call Q&A session are limited to asking one question following ELTP management’s opening statements.
To make the most of this Q&A opportunity, suggest that we come up with a list to share of top questions to ask:
[copy/paste list and add your question at the bottom]
1. ELI-200/SequestOx
A. FDA's Advisory Committee review of Pfizer's ALO 02/Troxyca ER determined that "Oxycodone can be selectively extracted from intact pellets
by a number of straightforward techniques and certain common solvents appear to be capable of removing naltrexone selectively from crushed pellets."
How do ELI-200/SequestOx's results compare if subjected to the same criteria?
B. Is a media/PR campaign planned if ELI-200/SequestOx receives FDA's approval and becomes the first and only IR ADT with label?
2. ELI-201.
A. Progress/status update.
B. There are multiple viable pathways to obtaining approval for ELI-201. Is it accurate to conclude that if anything other than ALO 02/Troxyca ER is
used as the direct comparator, then Phase 3 would be required?
C. Pfizer's antagonist ADF ALO-02 had less than impressive HAL results with crushed tablets orally ingested. How does Elite's antagonist ADF ELI-201 perform on HAL studies when crushed and orally ingested?
3. Progress/status update on ELI-202.
4. Has Elite entertained the sale of its generic line of business since it would provide capital needed to push the balance of the portfolio through FDA submission?
5. How much does a fluid bed dryer cost? Does Elite have the room to add a 2nd 1000 Kilo or will they need a new
manufacturing site and/or partner?
6. When can we expect the shareholder's meeting?
7. Tell about the connections with the Chinese - and what future developments are you expecting.
News 
Market Data 
Discover 
AI
